E. Şahin Et Al. , "Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617," MEDICINE , vol.102, no.47, 2023
Şahin, E. Et Al. 2023. Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617. MEDICINE , vol.102, no.47 .
Şahin, E., Kefeli, U., Zorlu, Ş., Seyyar, M., Ozkorkmaz Akdag, M., Can Sanci, P., ... Karakayali, A.(2023). Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617. MEDICINE , vol.102, no.47.
Şahin, Elif Et Al. "Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617," MEDICINE , vol.102, no.47, 2023
Şahin, Elif Et Al. "Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617." MEDICINE , vol.102, no.47, 2023
Şahin, E. Et Al. (2023) . "Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617." MEDICINE , vol.102, no.47.
@article{article, author={Elif Şahin Et Al. }, title={Prognostic role of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value in metastatic castration-resistant prostate cancer patients who underwent 177Lu-PSMA-617}, journal={MEDICINE}, year=2023}